Starting Drug Treatment Early Improves Outcomes for Crohn’s Disease Patients

A one-year study of 386 people found that receiving advanced treatment soon after diagnosis of Crohn’s disease improves outcomes for patients.

This disease is a lifelong inflammatory bowel disease; impact millions of peopleIn the world. Symptoms include abdominal pain, diarrhea, fatigue, and weight loss.

“These symptoms have a huge impact on people’s quality of life, education, relationships, and ability to work,” he says. Miles Parks at Cambridge University. “While there is no cure, there are ways to reduce some of these negative outcomes.”

Treatment often includes dietary changes, immunosuppressants, and steroids. In the UK, a drug called infliximab (an antibody that targets a specific protein in the body that is thought to contribute to intestinal inflammation) is given to people who regularly experience flare-ups of Crohn’s disease, or other mild symptoms. It can be prescribed to people who are not responding to. Treatment.

“This is a ‘step-up’ approach where treatment is progressively escalated in a reactive manner as the disease returns,” he says. Nurlaminnuralso at the University of Cambridge.

To see what happens if this more powerful treatment is used as early as possible, Parkes and Noor et al. studied 386 newly diagnosed Crohn’s disease patients aged 16 to 80 in the UK. Recruited people.

They were divided into two groups. One patient received infliximab immediately regardless of symptoms, and the other was treated with other Crohn’s disease drugs. If symptoms persist or continue to worsen, participants in the second group will also be prescribed infliximab, in line with a “step-up” approach.

After one year, 80 percent of patients who initially received infliximab had their symptoms under control over time, compared with only 15 percent of those who did not receive treatment immediately.

Additionally, only 0.5% of people in the group who received infliximab immediately required abdominal surgery for Crohn’s disease, compared to 4.5% in the second group.

The results of this study suggest that giving patients with Crohn’s disease intensive treatment as soon as they are diagnosed may be more effective in improving their lives, Dr. Noor said.

Parks said the extra money spent on medication would be balanced out by not having to pay for subsequent scans, colonoscopies and surgeries for people with repeated relapses.

“People with Crohn’s disease don’t want to be hospitalized or undergo surgery. They want to go out into the outside world and live their lives. Anything that speeds the path to remission. It can only be a good thing,” says Ruth Wakeman of the charity Crohn’s & Colitis UK.